Immusorba TR and Immusorba PH: Basics of Design and Features of Functions

Wiley - Tập 2 Số 3 - Trang 185-192 - 1998
Makoto Yoshida1, Yuichi Tamura1, Yukihiro Yamada1, Naokuni Yamawaki1, Yuhiko Yamashita1
1Research and Development Laboratory and Technical Department, Asahi Medical Co., Ltd., Oita, Japan

Tóm tắt

Abstract: Immusorba was reported by Yamazaki et al. to be the world's first practical immunoadsorbent in 1982. Since then, this immunoadsorbent has accumulated an abundance of clinical achievements. Immusorba has such unique functions that it is used in treating various diseases and holds possibilities for application to more diseases. Immusorba was designed as an artificial receptor for rheumatoid factor (RF) based on structural analysis of heat‐denaturated globulin. Subsequently, new substances that it can adsorb have been found as seen in reports on the adsorption performance of Immusorba to anti‐acetylcholine receptor antibodies (anti‐AChR Abs) and antiganglioside antibodies. Along with this, Immusorba has been used in treating a wide range of diseases. The greatest characteristic of Immusorba is that its adsorption capability is selective rather than specific, making it effective against a great number of diseases.

Từ khóa


Tài liệu tham khảo

Yamazaki Z, 1982, Efficiency and biocompatibility of new immunoadsorbent, Trans Am Soc Ar-tif Intern Organs, 28, 318

10.5059/yukigoseikyokaishi.43.1024

SatoT AnnoM AraiK YamawakiN KurodaT InagakiK.In vitro removal of anti‐acetylcholine receptor antibodies with a new immunoadsorbent in sera from myasthenia gravis patients.Prog Artif Organs. ISAO Press 1983:719–22.

10.1212/WNL.46.6.1644

Takashima H, 1989, Immunoadsorbent IM‐TR interacts at the hinge region of IgG, Ther Plasmapheresis, 8, 195

Okudaira K, 1984, Effect of immunoadsorbent treatment on auto‐antibody levels, Ther Plasmapheresis, 4, 149

Behm E, 1986, Interactions of IM‐P and IM‐T adsorbents with complement components, Ther Plasmapheresis, 6, 493

Fujita S, 1993, Changes in blood and plasma viscosities after plasmapheresis therapy, Ther Plasmapheresis, 12, 711

Shinoda T, 1993, Yanagisawa N. Immunoadsorption plasmapheresis and plasma exchange in Guillain‐Barre syndrome, Ther Plasmapheresis, 12, 531

10.1016/0955-3886(93)90046-W

Ichikawa H, 1996, Removal ability of IgG anti‐GQlb antibody in immunoadsorption therapy for Fisher syndrome–Comparison of the removal ability between tryptophan column and phenylalanine column, Clin Neurol, 36, 323

10.1016/0955-3886(95)00069-A

Shibuya N, 1985, Current practice in therapeutic plasmapheresis., 166

Shibuya N, 1989, Immunoadsorption therapy for MG: Multi‐center trial in single‐blind design, Ther Plasmapheresis, 8, 231

Shibamoto T, 1991, Study of immunoadsorbent therapy in five severe cases of myasthenia gravis, Ther Plasmapheresis, 9, 209

10.1212/WNL.45.2.338

Koh C‐S, 1994, Immunoadsorption plasmapheresis in polymyositis/dermatomyositis: Beneficial effects in four cases, Jpn J Apheresis, 13, 131

Shibuya N, 1984, Immunoadsorbent plasma perfusion therapy in patients with neuroimmunological disorders, Ther Plasmapheresis, 4, 165

Yamazaki Z, 1984, Effect of immunoadsorption on patient with rheumatoid arthritis or SLE, Trans Am Soc Artif Intern Organs, 30, 211

Kanazawa H, 1984, Change of lymphocyte subsets during plasmapheresis, Ther Plasmapheresis, 4, 561

Amasaki Y, 1989, Effect of immunoadsorption therapy on lupus nephritis using immunoadsorbent PH350 column, Ther Plasmapheresis, 8, 88

Yamawaki T, 1997, Effect of newly developed immunoadsorbent column (TR‐350S) on neurological disorders, Clin Pharm Ther, 7, 1233

Thông tin
Thông tin xuất bản

Wiley

Tập 2 Số 3

185-192

Thông tin tác giả